Abstract: The present invention features a composition comprising zinc pyrithione and silver sulfiadizine, a formulation thereof and a method of treating microbial infection using the composition.
Abstract: A method of treating pruritus (itching) in a subject in need thereof is carried out by administering the subject an active agent in a treatment effective amount, wherein the active agent is a superoxide dismuate (SOD) mimetic. The SOD mimetic can be a complex of a metal (e.g., manganese) and an organic ligand, with suitable organic ligands including porphyrins, polyamines, salens, nitroxides, and fullerenes. Compositions for carrying out such methods are also described.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
July 20, 2021
Assignees:
Duke University, BioMimetix JV, LLC
Inventors:
Ru-Rong Ji, Tong Liu, Ines Batinic-Haberle, David S. Warner, Kimberly C. Stone, James D. Crapo
Abstract: Citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof for use in the treatment of neurodegenerative diseases The disclosure subject matter is related to the use of citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof, in the treatment of neurodegenerative diseases that are positively influenced by the decrease of protein misfolding and/or aggregation, in particular by oral administration.
Type:
Grant
Filed:
March 17, 2016
Date of Patent:
June 15, 2021
Assignee:
UNIVERSIDADE DO MINHO
Inventors:
Patricia Espinheira De Sá Maciel, Andreia Cristiana Teixeira De Castro, Ana Luísa De Jales Monteiro De Sousa, Ana Sofia Teixeira Esteves, Nuno Jorge Carvalho Sousa
Abstract: The present invention provides a pharmaceutical composition for oral administration, comprising (a) 4 to 40% by weight of a taxane, (b) 10 to 30% by weight of a medium chain triglyceride, (c) 30 to 70% by weight of monooleoyl glycerol, (d) 5 to 30% by weight of a surfactant, and (e) 10 to 30% by weight of polyoxyl glyceryl fatty acid ester and a process for preparing the same.
Type:
Grant
Filed:
April 6, 2016
Date of Patent:
June 1, 2021
Assignee:
DAE HWA PHARMA. CO., LTD.
Inventors:
In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Han-Koo Lee
Abstract: The present invention relates to a type of aryl benzofuran amidated derivatives, the medical use thereof, and the preparation method; said derivatives have antioxidation activity, and xanthine oxidase inhibitory activity, and can be used for antioxidation and for preparing compositions, drugs and health products and treating gout and hyperuricemia.
Abstract: The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful for the treatment of dermatological diseases and the symptoms and underlying causes of such dermatological diseases are also disclosed.
Type:
Grant
Filed:
February 6, 2019
Date of Patent:
June 1, 2021
Assignee:
Evologie LLC
Inventors:
Gary I. Weinberger, H. Robert Nagel, Richard A. Brown
Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
May 25, 2021
Assignee:
NeOncTechnologies, Inc.
Inventors:
Thomas Chen, Daniel Levin, Satish Pupalli
Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation. For example, salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment.
Type:
Grant
Filed:
March 23, 2015
Date of Patent:
May 11, 2021
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
Type:
Grant
Filed:
February 1, 2016
Date of Patent:
April 20, 2021
Assignees:
MEI PHARMA, INC., THE SPANISH NATIONAL CANCER RESEARCH CENTRE
Inventors:
Daniel P. Gold, Miguel Quintela-Fandino
Abstract: Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.
Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusion. The invention further relates to treating various diseases or disorders.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
April 13, 2021
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
March 16, 2021
Assignees:
Io Therapeutics, Inc., Trustees of Dartmouth College
Inventors:
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Abstract: Provided are methods for treating multiple sclerosis using a continuous regimen of estrogen in combination with periodic administration of a progestogen.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
October 13, 2020
Assignee:
The Regents of the University of California
Abstract: In one aspect, the present application relates to an aminothiol-conjugate of formula (I), wherein Core Linker R1, R2, R3, m, n, and p are as described above. The present invention also relates to a method of treating a subject in need of aminothiol therapy using an aminothiol-conjugate of formula (I).
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
September 22, 2020
Assignee:
THE BURLINGTON HC RESEARCH GROUP, INC.
Inventors:
Dale M. Walker, Vernon E. Walker, Tsvetelina I. Lazarova, Steven W. Riesinger
Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
September 15, 2020
Assignees:
Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.
Type:
Grant
Filed:
January 5, 2018
Date of Patent:
July 28, 2020
Assignee:
PALVELLA THERAPEUTICS, INC.
Inventors:
Wesley Harton Kaupinen, Braham Shroot, Simon David Betson, Charles Rodney Greenaway Evans, Marc Barry Brown
Abstract: This application describes compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders.
Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
June 30, 2020
Assignees:
Io Therapeutics, Inc., Trustees of Dartmouth College
Inventors:
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Abstract: The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
Type:
Grant
Filed:
October 6, 2014
Date of Patent:
May 19, 2020
Assignees:
Io Therapeutics, Inc., Trustees of Dartmouth College
Inventors:
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders